Sponsor Dossier
Interpharma
Sponsor Dossier for Interpharma. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: APOMINE
- Brand: BORTEZOMIB EVER PHARMA
- Brand: CABAZITAXEL EVER PHARMA
- Brand: CARBETOCIN
- Brand: DEXMEDETOMIDINE EVER PHARMA
- Brand: EPHEDRINE
- Brand: ESMOLOL
- Brand: FULVESTRANT
- Device (sponsor): Infusion pump medication reservoir set
- Device (sponsor): Cartridge-accepting autoinjector, mechanical
- Device (sponsor): General-purpose infusion pump, battery-powered
- Device (sponsor): STAT-ON Parkinson's Holter - Neuromuscular motion disorder long-term ambulatory recorder/analyser
- Device (sponsor): D-mine Infusion Set - Electric infusion pump administration set
- Device (sponsor): Hypodermic needle, single-use, sterile
- Device (sponsor): Lavage handpiece tip
- Device (sponsor): Perioperative methylene blue stain
- Device (sponsor): Sentinel lymph node dye
- Device (sponsor): D-Mine Pump - General-purpose infusion pump, battery-powered
- Device (sponsor): Infusion pump cassette
- Device (sponsor): Instillagel Almed (Lignocaine 2% and Chlorhexidine 0.05%) - General-body orifice lubricant, sterile
- Device (sponsor): Basic insulin pen, replaceable-cartridge
- Device (sponsor): Instillagel Lido (Lignocaine 2%) - General-body orifice lubricant, sterile
- Device (sponsor): Endotherapy cannula, flexible, single-use
About
Interpharma is an Australian Private Company with ABN 19099877899, registered in New South Wales. The company is active and registered for GST from 2002.
Portfolio
Interpharma has 19 brands on the ARTG, with all 19 cleared as indexable brands. All 19 brands have Product Information on file. One brand is PBS-listed and four brands have PBAC outcomes on record. The portfolio includes brands such as APOMINE, BORTEZOMIB EVER PHARMA, CABAZITAXEL EVER PHARMA, CARBETOCIN, DEXMEDETOMIDINE EVER PHARMA, EPHEDRINE, ESMOLOL, FULVESTRANT, GENTAMICIN, Heparin, INSTILLAGEL, and KETAMINE INTERPHARMA.
Therapeutic focus
— Oncology: 4 brands — Pain & Anaesthesia: 3 brands — Neurology: 3 brands — Infectious Disease: 2 brands — Cardiology: 2 brands — Other: 2 brands — Pain Management: 1 brand — Women's Health: 1 brand — Immunology: 1 brand
PBS footprint
One brand in Interpharma's portfolio is PBS-listed, with the portfolio most recently touching the PBS schedule on 2026-05-01.
Regulatory activity
Interpharma's most recent PBAC outcome was recorded on 2023-03-01, with four brands holding PBAC outcomes on record.